AMR Stakeholder Profile
Focus area/active in: Therapeutics
Company/Organisation type: SME
BioVersys AG is a privately owned Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance and targeted microbiome modulation. BioVersys addresses the high unmet medical need for new treatments against life threatening resistant bacterial infections. Our most advanced R&D programs are in preclinical development for nosocomial infections, and Tuberculosis in collaboration with GSK. In 2020 BioVersys plans to launch its first Phase I clinical trials.
Would you like to meet Bioversys virtually during the AMR Conference week?
Get in touch!
Head Business Development
Please fill out the form below to get in touch with us.